Share Twitter LinkedIn Facebook Email Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1 & 2 | Response Rate Doubled Comparing Talazoparib at Annual Meeting 2018
2025 Breast Cancer Updates: Dr. Evanthia Roussos Torres on Biomarkers, Immunotherapy, and the Future of Treatment – MOASC Breast 6 Mins Read
FDA Approves Datopotamab Deruxtecan / Datroway from Eli Lilly in Treatment for Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer Breast 2 Mins Read